Potential use of HMG-CoA reductase inhibitors for osteoporosis

Annals of Pharmacotherapy

Volumn 36, Issue 4, 2002, Pages 671-678

  Cushenberry, Lolita M ^a   Rodriguez de Bittner, Magaly ^a   LeDuff, Michel ^a  

^a NONE   (United States)

Author keywords

Fractures; HMG CoA reductase inhibitors; Osteoporosis; Prevention

Indexed keywords

ALENDRONIC ACID; CALCIUM; CONJUGATED ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; STATINE DERIVATIVE; VITAMIN; VITAMIN D;

ARTICLE; BONE ATROPHY; CLINICAL TRIAL; CONSTIPATION; EPISTAXIS; FRACTURE; HEADACHE; HEARTBURN; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INSOMNIA; META ANALYSIS; MIGRAINE; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; SINUSITIS; THORAX PAIN; VAGINA BLEEDING; VITAMIN SUPPLEMENTATION;

EID: 0036205571     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A072     Document Type: Article

References (20)

1. Osteoporosis: Epidemiology, diagnosis, and treatment
2. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation
3. Pathogenesis of osteoporosis
4. The management of osteoporosis
5. Glucocorticoid-induced osteoporosis
6. Corticosteroid-induced osteoporosis
7. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis
8. Osteoporosis prevention, diagnosis, and therapy
9. Stimulation of bone formation in vitro and in rodents by statins
10. Inhibitors of hydroxymethyl glutaryl-coenzyme A reductase and risk of fracture among older women
11. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
12. HMG-CoA reductase inhibitors and the risk of fractures
13. Use of statins and risk of fractures
14. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomized controlled trial
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
16. Current perspectives on statins
17. Do statins prevent both cardiovascular disease and fracture?
18. New insights into the pharmacodynamic and pharmacokinetic properties of statins
19. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group